Financial Report: Bristol-Myers Squibb

Bristol-Myers Squibb

2Q Revenues: $4.9 billion (+17%)

2Q Earnings: $1.2 billion (loss of $130k 2Q15)

YTD Revenues: $9.3 billion (+13%)

YTD Earnings: $2.4 billion (+124%)

Comments: Growth in the quarter was driven by Opdivo, which grew by $718 million to $840 million; Eliquis, which grew 78% to $777 million; Orencia sales were up 29% to $593 million; Hepatitis C Franchise, which grew 14% to $546 million; and Sprycel, which grew 11% to $451 million. Baraclude sales were down 13% to $299 million. Reyataz Franchise sales were $247 million, down 22% and Sustiva Franchise sales were down 12% to $271 million due to loss of exclusivity. R&D expenses were down 32% to $1.3 billion in the quarter.